Document is current
Any future updates will be listed below
-
Authors
Viljoen, Adie https://orcid.org/0000-0002-3125-7998
Pantalone, Kevin M. https://orcid.org/0000-0002-3897-4551
Galindo, Rodolfo J. https://orcid.org/0000-0002-9295-3225
Cui, Xuewei
Huh, Ruth https://orcid.org/0000-0002-7725-088X
Hemmingway, Andrea https://orcid.org/0000-0002-5856-5114
Fernández Landó, Laura https://orcid.org/0000-0002-0969-6214
Patel, Hiren https://orcid.org/0000-0003-2463-4916
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03987919 at ClinicalTrials.govnct03882970 at ClinicalTrials.govDocuments that mention this clinical trial
Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide
https://doi.org/10.1007/s13300-023-01457-7
Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics
https://doi.org/10.1007/s13300-024-01660-0
Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3
https://doi.org/10.1007/s13300-023-01398-1
Documents that mention this clinical trial
Improved Glycaemic and Weight Management Are Associated with Better Quality of Life in People with Type 2 Diabetes Treated with Tirzepatide
https://doi.org/10.1007/s13300-023-01457-7
Post Hoc Analysis of SURPASS-1 to -5: Efficacy and Safety of Tirzepatide in Adults with Type 2 Diabetes are Independent of Baseline Characteristics
https://doi.org/10.1007/s13300-024-01660-0
Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients with Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3
https://doi.org/10.1007/s13300-023-01398-1
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 5 January 2023
Accepted: 14 March 2023
First Online: 31 March 2023
